Arsenic Trioxide

證據等級: L5

預測適應症: 10 個

Arsenic Trioxide: Repurposing Evaluation — Evidence Pack Incomplete

One-Sentence Summary

Arsenic Trioxide (DB01169) is a well-established antineoplastic agent; however, this Evidence Pack contains no TxGNN predicted indications, and critical data fields — including original indications, mechanism of action, and safety warnings — are either missing or not yet populated. A full repurposing evaluation cannot be completed at this stage. The overall evidence level is L5 and the recommended decision is Hold pending data remediation.

Quick Overview

Item	Content
Original Indication	Not specified in Evidence Pack
Predicted New Indication	None — no TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model data not yet available
Taiwan Market Status	✗ Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN predictions are present in this Evidence Pack (predicted_indications: []), so a data-driven repurposing rationale cannot be generated at this time.

Additionally, the mechanism of action is flagged as Data Gap DG002 (severity: High), which means even a qualitative mechanistic bridge between a source indication and a candidate new indication cannot be constructed. Until DrugBank API data is retrieved and parsed, any mechanistic claim would be speculative.

Currently, detailed mechanism of action data is not available. Based on known pharmacological class, Arsenic Trioxide belongs to the arsenic compound category with established antineoplastic activity; however, this must be formally confirmed via DrugBank (DB01169) before it can be used to support a repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Taiwan Market Information

Arsenic Trioxide is currently not marketed in Taiwan. No drug authorizations are on file (total licenses = 0). No license table can be generated.

Cytotoxicity

Arsenic Trioxide belongs to a class of antineoplastic agents (arsenic compounds); a cytotoxicity section is included accordingly.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Arsenic compound
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential, liver function tests, renal function, ECG (QTc interval), serum electrolytes (potassium, magnesium)
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Please refer to the package insert for safety information.

Both key warnings (DG001, severity: Blocking) and contraindications are listed as data gaps. The TFDA package insert PDF must be retrieved and parsed before any safety screening can proceed. DDI query returned no results (status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is critically incomplete — there are no TxGNN predicted indications, no mechanism of action data, and safety information is blocked pending package insert retrieval. A repurposing evaluation cannot responsibly proceed until these gaps are closed.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve and parse the TFDA package insert PDF to extract warnings and contraindications; this is a prerequisite for the S1 safety screening gate
[DG002 — High] Query DrugBank API (DB01169) to populate mechanism of action, drug categories, and toxicity profile
Re-run TxGNN pipeline after data gaps are resolved to generate predicted_indications — without this, no repurposing candidate can be evaluated
DDI re-query once the drug identity and formulation details are confirmed in DrugBank
Taiwan market status cross-check — confirm whether any foreign authorizations (e.g., FDA Trisenox, EMA Trisenox) could support a bridging regulatory strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.